Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma

Author(s): N. E. Fullerton, M. Boyd, S. C. Ross, S. L. Pimlott, J. Babich, D. Kirk, M. R. Zalutsky, R. J. Mairs

Journal Name: Medicinal Chemistry

Volume 1 , Issue 6 , 2005

Become EABM
Become Reviewer
Call for Editor


Targeted radiotherapy using radiolabelled meta-iodobenzylguanidine (MIBG) is a promising treatment option for bladder cancer, restricting the effects of radiotherapy to malignant cells thereby increasing efficacy and decreasing morbidity of radiotherapy. We investigated the efficacy of a combined gene therapy and targeted radiotherapy approach for bladder cancer using radiolabelled MIBG. The effectiveness of alternative radiohalogens and alternative preparations of radiolabelled MIBG for this therapeutic strategy were compared. Bladder cancer cells, EJ138, were transfected with a gene encoding the noradrenaline transporter (NAT) under the control of a tumour specific telomerase promoter, enabling them to actively take up radiolabelled MIBG. This resulted in tumourspecific cell kill. Uptake and retention of radioactivity in cells transfected with the NAT gene were compared with that obtained in cells transfected with the sodium iodide symporter (NIS) gene. Substantially greater uptake and longer retention of radioactivity in NAT-transfected cells was observed. Carrier-added (c.a.) [131I]MIBG, no-carrier added (n.c.a.) [131I]MIBG, and [211At]-labelled benzylguanidine (i.e. [211At] meta-astatobenzylguanidine (MABG)) were compared with respect to efficiency of induction of cell kill. N.c.a[131I]MIBG was more cytotoxic than c.a.[131I]MIBG. However, the α- emitter [211At]MABG was, by three orders of magnitude, more effective in causing tumour cell kill than the β-emitter [131I]MIBG. We conclude that NAT gene transfer combined with the administration of n.c.a.[131I]MIBG or [211At]MABG, is a promising novel treatment approach for bladder cancer therapy.

Keywords: bladder cancer, gene therapy, nat, nis, [131I]mibg, [211at]mabg

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [611 - 618]
Pages: 8
DOI: 10.2174/157340605774598090
Price: $65

Article Metrics

PDF: 6